ATE332364T1 - Verfahren zur gewinnung von purifizierter virenzuammensetzung - Google Patents

Verfahren zur gewinnung von purifizierter virenzuammensetzung

Info

Publication number
ATE332364T1
ATE332364T1 AT00906444T AT00906444T ATE332364T1 AT E332364 T1 ATE332364 T1 AT E332364T1 AT 00906444 T AT00906444 T AT 00906444T AT 00906444 T AT00906444 T AT 00906444T AT E332364 T1 ATE332364 T1 AT E332364T1
Authority
AT
Austria
Prior art keywords
purified virus
virus composition
obtaining purified
viral
particles
Prior art date
Application number
AT00906444T
Other languages
English (en)
Inventor
Michel Koehl
David Gaillac
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of ATE332364T1 publication Critical patent/ATE332364T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10051—Methods of production or purification of viral material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00906444T 1999-02-22 2000-02-21 Verfahren zur gewinnung von purifizierter virenzuammensetzung ATE332364T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9902167 1999-02-22

Publications (1)

Publication Number Publication Date
ATE332364T1 true ATE332364T1 (de) 2006-07-15

Family

ID=9542357

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00906444T ATE332364T1 (de) 1999-02-22 2000-02-21 Verfahren zur gewinnung von purifizierter virenzuammensetzung

Country Status (8)

Country Link
US (1) US7264958B1 (de)
EP (1) EP1155120B1 (de)
JP (2) JP4802366B2 (de)
AT (1) ATE332364T1 (de)
AU (1) AU774437B2 (de)
CA (1) CA2364934C (de)
DE (1) DE60029195T2 (de)
WO (1) WO2000050573A1 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL343630A1 (en) 1998-04-22 2001-08-27 Genvec Inc Efficient purification of adenovirus
ATE302268T1 (de) * 2001-12-20 2005-09-15 Bavarian Nordic As Methode zur gewinnung und reinigung von poxviren aus infizierten zellen
CA2678736A1 (en) 2003-07-21 2005-02-17 Transgene S.A. Novel multifunctional il-2 - il-18 fusion proteins
JP2007522814A (ja) 2004-02-23 2007-08-16 クルセル ホランド ベー ヴェー ウイルスの精製方法
ATE412737T1 (de) 2005-04-11 2008-11-15 Crucell Holland Bv Virusreinigung mit ultrafiltration
JP4670583B2 (ja) * 2005-10-20 2011-04-13 チッソ株式会社 水溶性カチオン性磁気微粒子を用いた脂質ベシクルの分離又は検出方法
US9375499B2 (en) 2006-07-14 2016-06-28 Wisconsin Alumni Research Foundation Adsorptive membranes for trapping viruses
EP2390340A3 (de) 2007-01-30 2012-02-22 Transgene SA Papillomavirus E1 und E2-Polypeptiden mit reduziertem Identitätsanteil kodierender Vektor
KR101504392B1 (ko) 2008-11-03 2015-03-19 크루셀 홀란드 비.브이. 아데노바이러스 벡터의 제조방법
WO2010084100A1 (en) 2009-01-20 2010-07-29 Transgene Sa Soluble icam-1 as biomarker for prediction of therapeutic response
ES2555858T3 (es) 2009-03-24 2016-01-11 Transgene Sa Biomarcador para el control de pacientes
HRP20140262T1 (hr) 2009-04-17 2014-04-25 Transgene Sa Biomarker za praä†enje pacijenata
DK2452194T3 (en) 2009-07-10 2015-11-30 Transgene Sa Biomarker PATIENT SELECTION AND RELATED PRACTICES
BR112012002628B1 (pt) 2009-08-07 2021-09-08 Transgene Sa Composição imunogênica, molécula de ácido nucleico, vetor, partícula viral infecciosa, micro-organismo transgênico, composição, usos da composição imunogênica e kit de partes
NZ601424A (en) 2010-02-15 2014-07-25 Crucell Holland Bv Method for the production of ad26 adenoviral vectors
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
KR20130122947A (ko) * 2010-10-27 2013-11-11 필립모리스 프로덕츠 에스.에이. 팽창성 베드 크로마토그래피를 사용하여 식물로부터 바이러스 유사 입자를 포획하는 방법
WO2012076715A1 (en) 2010-12-09 2012-06-14 Institut Pasteur Mgmt-based method for obtaining high yield of recombinant protein expression
JP2014527799A (ja) 2011-08-26 2014-10-23 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション 変異型ｐｂ２遺伝子セグメントを有する弱毒化生ワクチンとしてのインフルエンザウイルス
TW201321016A (zh) 2011-09-29 2013-06-01 Transgene Sa 免疫療法組成物及用於治療ｃ型肝炎病毒感染之療程（二）
WO2013045658A1 (en) 2011-09-29 2013-04-04 Transgene Sa Immunotherapy composition and regimen for treating hepatitis c virus infection
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
CA2878800A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterial antigen vaccine
EP3587455A1 (de) 2012-10-23 2020-01-01 Emory University Gm-csf- und il-4-konjugate, zusammensetzungen und zugehörige verfahren
KR20210054067A (ko) 2013-06-14 2021-05-12 싸이오서스 테라퓨틱스 엘티디. 유형 b 아데노바이러스에 대한 투여 요법 및 제형
EP3831398A1 (de) 2013-10-25 2021-06-09 PsiOxus Therapeutics Limited Onkolytische adenoviren, die mit heterologen genen ausgestattet sind
RU2695462C2 (ru) 2014-01-09 2019-07-23 Трансген Са Гибридизация гетероолигомерных микобактериальных антигенов
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
CN107949397A (zh) 2015-02-13 2018-04-20 特兰斯吉恩股份有限公司 免疫治疗疫苗和抗体组合治疗
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
MY193281A (en) 2015-12-17 2022-09-30 Psioxus Therapeutics Ltd Group b adenovirus encoding an anti-tcr-complex antibody or fragment
JP2019510481A (ja) 2016-02-19 2019-04-18 ウィスコンシン アルムニ リサーチ ファンデイション ワクチン開発のための改善されたｂ型インフルエンザウイルス複製
WO2017191147A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
JP2019532621A (ja) 2016-08-29 2019-11-14 サイオクサス セラピューティクス リミテッド 二重特異性Ｔ細胞エンゲージャー（ＢｉＴＥ）で武装したアデノウイルス
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
US20190328869A1 (en) 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
JP7078620B2 (ja) 2016-11-16 2022-05-31 イミュノミック セラピューティックス， インコーポレイテッド アレルギーの治療のための核酸
ES3004084T3 (en) 2017-04-22 2025-03-11 Immunomic Therapeutics Inc Improved lamp constructs
KR20200016224A (ko) 2017-05-02 2020-02-14 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 lamp (리소솜 연관 막 단백질) 구축물
EP3700562A1 (de) 2017-10-25 2020-09-02 Wisconsin Alumni Research Foundation (WARF) Rekombinante influenzaviren mit stabilisiertem ha zur replikation in eiern
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation
US12398195B2 (en) 2018-05-15 2025-08-26 Immunomic Therapeutics, Inc. Lamp constructs comprising allergens
JP7783047B2 (ja) * 2018-08-07 2025-12-09 ウィスコンシン アルムニ リサーチ ファンデイション 組換えの生物学的に封じ込められたフィロウイルスワクチン
EP3840780A1 (de) 2018-08-20 2021-06-30 Wisconsin Alumni Research Foundation Vektoren zur auslösung von immunantworten auf nicht-dominante epitope im hämagglutinin (ha)-protein
AU2019344006B2 (en) 2018-09-21 2025-11-27 University Of Connecticut Compositions and methods to restore paternal UBE3A gene expression in human Angelman Syndrome
EP3883682A1 (de) * 2018-11-22 2021-09-29 Fixed Phage Limited Herstellung immobilisierter bakteriophagen
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
US11851648B2 (en) 2019-02-08 2023-12-26 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
WO2020223699A1 (en) 2019-05-01 2020-11-05 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
GB201909081D0 (en) * 2019-06-25 2019-08-07 Psioxus Therapeutics Ltd Method
WO2021041624A2 (en) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Recombinant influenza viruses with stabilized ha for replication in eggs
CN114641306A (zh) 2019-10-18 2022-06-17 免疫治疗有限公司 包含癌抗原的改良lamp构建物
IL293051A (en) 2019-11-18 2022-07-01 Janssen Biotech Inc Vaccines based on mutant calr and jak2 and their uses
JP2023511444A (ja) 2020-01-24 2023-03-17 ウィスコンシン アルムニ リサーチ ファンデイション 安定化されたｎａを有する組換えインフルエンザウイルス
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
US12290562B2 (en) 2020-03-25 2025-05-06 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
JP2023521194A (ja) 2020-04-13 2023-05-23 ヤンセン バイオテツク，インコーポレーテツド Ｐｓｍａ及びｓｔｅａｐ１ワクチン並びにそれらの使用
EP4175721A1 (de) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostata-neoantigene und ihre verwendungen
WO2022009051A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. A method for determining responsiveness to prostate cancer treatment
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
US20230241530A1 (en) * 2022-02-01 2023-08-03 W. L. Gore & Associates, Inc. Affinity chromatography devices containing a heat treated fibrillated polymer membrane for the separation of mrna and viral vectors from an aqueous mixture
EP4508071A1 (de) 2022-04-10 2025-02-19 Immunomic Therapeutics, Inc. Bicistronische lampenkonstrukte mit immunreaktionserhöhenden genen und verfahren zur verwendung davon
WO2025158316A1 (en) 2024-01-26 2025-07-31 Janssen Biotech, Inc. Ovarian neoantigens and use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0328256A1 (de) * 1988-01-21 1989-08-16 Owens-Corning Fiberglas Corporation Glasfaser, überzogen mit Agarose, zur Verwendung als Säulenpackung oder chromatographisches Medium in Biotrennungen
GB8806605D0 (en) 1988-03-19 1988-04-20 Robinson E Composite adsorbents
SE9101149D0 (sv) 1991-04-17 1991-04-17 Pharmacia Lkb Biotech Beads for down stream processing
DE4128953A1 (de) * 1991-08-30 1993-03-04 Basf Ag Verfahren zur kultivierung von saeugerzellen im fliessbettreaktor
US5837520A (en) * 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
FR2737730B1 (fr) 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc Procede de purification de virus par chromatographie
CA2625279A1 (en) * 1995-08-30 1997-03-06 Genzyme Corporation Chromatographic purification of adenovirus and aav
US6027888A (en) * 1996-04-05 2000-02-22 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide-bond containing eukaryotic proteins in bacterial cells
US6485958B2 (en) 1996-07-01 2002-11-26 Gencell Sa Method for producing recombinant adenovirus
WO1998022588A2 (en) 1996-11-20 1998-05-28 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
EP0948601B1 (de) 1996-12-13 2007-02-14 Schering Corporation Methoden zur virus-reinigung
SE9700383D0 (sv) * 1997-02-04 1997-02-04 Pharmacia Biotech Ab An adsorption/separation method and a medium for adsorption/separation
EP0972374A1 (de) 1998-02-04 2000-01-19 Sun Microsystems, Inc. Verfahren und vorrichtung zur effizienten authentifizierung und prüfung der integrität unter verwendung von hierarchischem hashing
PL343630A1 (en) 1998-04-22 2001-08-27 Genvec Inc Efficient purification of adenovirus

Also Published As

Publication number Publication date
JP4802366B2 (ja) 2011-10-26
US7264958B1 (en) 2007-09-04
DE60029195D1 (de) 2006-08-17
WO2000050573A1 (fr) 2000-08-31
EP1155120B1 (de) 2006-07-05
CA2364934A1 (fr) 2000-08-31
DE60029195T2 (de) 2007-06-28
EP1155120A1 (de) 2001-11-21
AU2811800A (en) 2000-09-14
CA2364934C (fr) 2011-10-18
AU774437B2 (en) 2004-06-24
JP2002536992A (ja) 2002-11-05
JP2011120596A (ja) 2011-06-23

Similar Documents

Publication Publication Date Title
DE60029195D1 (de) Verfahren zur gewinnung von purifizierter virenzuammensetzung
ATE324436T1 (de) Verfahren zur reinigung von menschlichen, dem papillomavirus ähnlichen partikeln.
ATE306252T1 (de) Verfahren zur herstellung kristalliner partikel zur inhalation
ATE278785T1 (de) Neues verfahren zur gewinnung und reinigung von fusionsproteinen
ATE322252T1 (de) Verfahren zur herstellung und sammlung von kristallinen partikeln
DE60114348D1 (de) Verfahren zur Reinigung von Gasen
DE69637509D1 (de) Verfahren zur reinigung von faktor-ix
DE69908998D1 (de) Verfahren zur Herstellung von Kohlenstoff
DE69703957D1 (de) Verfahren zur Herstellung von kristallinen Ceroxidteilchen.
AU1811301A (en) Methods for removal, purification, and concentration of viruses, and methods of therapy based thereupon
DE59800264D1 (de) Verfahren zur Herstellung von SiO2-Granulat
DE60132094D1 (de) Verfahren zur Herstellung von gereinigten Partikeln
DE60120819D1 (de) Verfahren zur adsorptiven Trennung von Kohlendioxid
DE60330146D1 (de) Verfahren zur reinigung von fibrinogen
DE60203975D1 (de) Verfahren zur Herstellung von magnetischen Teilchen, magnetische Teilchen und magnetischer Werkstoff
DE69531308D1 (de) Verfahren zur Herstellung von gereinigten papillomavirus Proteinen
DE60011396D1 (de) Verfahren zur herstellung von iopamidol
AU2003279240A1 (en) Methods for purifying viral particles for gene therapy
ATE509889T1 (de) Verfahren zur herstellung von granulatförmigem umhüllten natriumpercarbonat und verfahrensgemäss erhältliches produkt
DE69931976D1 (de) Verfahren zur Herstellung von Aminophosphinen und Aminophosphinoxiden, Zwischenprodukte dafür
DE60032077D1 (de) Verfahren zur dehalogenierung von kohlenwasserstoffhaltigen kohlenstoff-kohlenstoff doppelbindungen
DE60129907D1 (de) Verfahren zur Reinigung von Isophthalonitril
DE60002020D1 (de) Verfahren zur Herstellen von hochreinem Xylitol
AU2003265052A1 (en) Process for the purification of recombinant proteins from complex media and purified proteins obtained thereby
DE59912502D1 (de) Verfahren zur herstellung von enantiomerenreinem n-methyl- n- (1s)- 1-phenyl- 2-((3s)-3- hydroxypyrrolidin- 1-yl)ethyl]- 2,2- diphenylacetamid

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1155120

Country of ref document: EP